Peroxiredoxin v inhibits emodin-induced gastric cancer cell apoptosis via the ROS/Bcl2 pathway

15Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Peroxiredoxin (Prx) protein family is aberrantly expressed in various cancers including gastric cancer. Among the six family members, Prx V has been known as an antioxidant enzyme which scavenges intracellular reactive oxygen species (ROS) and modulates cellular apoptosis. This study aimed at investigating the role of Prx V in apoptosis of gastric cancer cells. Materials and Methods: Stably constructed Prx V knockdown, over-expression and mock AGS cells (a human gastric adenocarcinoma cell line) were used to study the effect of Prx V on emodin-induced apoptosis by western blotting, cell viability, apoptosis and ROS detection assays. Results: Overexpression of Prx V significantly decreased emodin-induced cellular apoptosis and ROS levels compared to Mock and Prx V knockdown AGS cells. Also, overexpression of Prx V down-regulated the expression of proapoptotic proteins, Bad and cleaved PARP, and increased the expression of anti-apoptotic protein, Bcl2. Conclusion: Prx V suppresses AGS cell apoptosis via scavenging intracellular ROS and modulating apoptosis-related markers.

Cite

CITATION STYLE

APA

Jin, Y. Z., Sun, H. N., Liu, Y., Lee, D. H., Kim, J. S., Kim, S. U., … Jin, Y. (2019). Peroxiredoxin v inhibits emodin-induced gastric cancer cell apoptosis via the ROS/Bcl2 pathway. In Vivo, 33(4), 1183–1192. https://doi.org/10.21873/invivo.11589

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free